Skip to Main content Skip to Navigation
Journal articles

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization

Anke Fuchs 1 Mateusz Gliwiński 2 Nathali Grageda 3 Rachel Spiering 4 Abul K Abbas 5 Silke Appel 6 Rosa Bacchetta 7 Manuela Battaglia 8 David Berglund 9 Bruce Blazar 10 Jeffrey A. Bluestone 5 Martin Bornhäuser 1 Anja ten Brinke 11 Todd M Brusko 12 Nathalie Cools 13, 14 Maria Cristina Cuturi 15 Edward Geissler 16 Nick Giannoukakis 17 Karolina Gołab 18 David A Hafler 19 S Marieke van Ham 11 Joanna Hester 20 Keli Hippen 10 Mauro Di Ianni 21 Natasa Ilic 22 John Isaacs 4, 23 Fadi Issa 20 Dorota Iwaszkiewicz-Grześ 2 Elmar Jaeckel 24 Irma Joosten 25 David Klatzmann 26 Hans Koenen 25 Cees van Kooten 27 Olle Korsgren 28, 29 Karsten Kretschmer 30, 31 Megan Levings 32 Natalia Maria Marek-Trzonkowska 2 Marc Martinez-Llordella 3 Djordje Miljkovic 22 Kingston H G Mills 33 Joana P Miranda 34 Ciriaco A Piccirillo 35 Amy L Putnam 5 Thomas Ritter 36 Maria Grazia Roncarolo 37 Shimon Sakaguchi 38 Silvia Sánchez-Ramón 39 Birgit Sawitzki 40 Ljiljana Sofronic-Milosavljevic 22 Megan Sykes 41 Qizhi Tang 5 Marta Vives-Pi 42 Herman Waldmann 20 Piotr Witkowski 43 Kathryn Wood 20 Silvia Gregori 8 Catharien M U Hilkens 4 Giovanna Lombardi 3 Phillip Lord 4 Eva M Martinez-Caceres 42, 44 Piotr Trzonkowski 2 
15 Team 1 - U1064 Inserm - CRTI - Dendritic cells and immunoregulation in transplantation and immunopathology
U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
Abstract : Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Document type :
Journal articles
Complete list of metadata
Contributor : Sylvie Le Bihan Connect in order to contact the contributor
Submitted on : Monday, June 17, 2019 - 3:00:38 PM
Last modification on : Friday, August 5, 2022 - 3:05:12 PM


Publication funded by an institution



Anke Fuchs, Mateusz Gliwiński, Nathali Grageda, Rachel Spiering, Abul K Abbas, et al.. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, Frontiers, 2018, 8, ⟨10.3389/fimmu.2017.01844⟩. ⟨inserm-02157859⟩



Record views


Files downloads